Sanofi-Aventis to invest in R&D in Spain
Business Investments
01 Apr 2012
France-based pharmaceutical company Sanofi-aventis plans to invest $1.3 million in research and development (R&D) projects of Barcelona's international biomedical research institute CRG.
The projects include cell reprogramming, the application of synthetic biology technology to treat lung diseases, the influence of genes as factor for some diseases and tuberculosis treatment, the director of CRG, Luis Serrano, said.
Source: IPA WORLD, 8/3/2012
Related News and Success stories.
-
27 Nov 2025
See more easyJet chooses Barcelona for its first Digital Hub in EuropeeasyJet chooses Barcelona for its first Digital Hub in Europe
-
12 Nov 2025
See more American tech company Infor inaugurates its new offices in Barcelona's 22@ districtAmerican tech company Infor inaugurates its new offices in Barcelona's 22@ district
-
10 Nov 2025
See more Chinese group Zhejian Aixiner Stockings to resume nylon yarn production at the former Nylstar factoryChinese group Zhejian Aixiner Stockings to resume nylon yarn production at the former Nylstar factory
-
04 Nov 2025
See more AstraZeneca invests €1.3 billion in its Barcelona headquarters, a global hub for biomedical researchAstraZeneca invests €1.3 billion in its Barcelona headquarters, a global hub for biomedical research
